Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Annual Product Quality Review

Annual Product Quality Review

View Detailed Analysis

Analytics Overview

7
Form 483s Issued
0
483s converted to WL
7
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
14 Nov 2023
Carma Laboratories, Inc.
Drugs
05 May 2023
Brenntag Great Lakes, LLC
Drugs
03 Mar 2023
H J Harkins Company Inc dba Pharma Pac
Drugs
13 Jan 2023
Sina Health Inc
Drugs
20 Dec 2022
Orly International, Inc.
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Gavin T Cua
2
0
Nibin Varghese
2
0
Jonah S Ufferfilge
1
0
Justin A Boyd
1
0
Saleem A Akhtar
1
0
TITLE/ COMPANY Issue Date Status Details
Written procedures are not followed for evaluations conducted to review records associated with batches
Carma Laboratories, Inc.
14 Nov 2023 Normal Justification: The deficiencies in conducting and closing APRs directly fall under Annual Product Quality Review as process type.
Excerpt: Specifically, Your firm failed to perform Annual Product Review (APR) for Domestic Lip Balm Stick and Domestic Lip Balm Tube for the year of 2022. According to your written procedure, individual APR are completed (b) (4) . Additionally, your procedure is deficient for the closure of APRs on a timely manner. For example, APR for Domestic Lip Balm Stick review period (1/1/2021 - 12/31/2021) was not completed until 12/29/2022.
View Details
Failure of your quality unit to perform an annual product review
Brenntag Great Lakes, LLC
05 May 2023 Normal Justification: The observation specifically mentions a failure to perform annual product reviews, which directly relates to the 'Annual Product Quality Review' process type.
Excerpt: Failure of your quality unit to perform an annual product review. Specifically, Your Quality Unit failed to perform annual product review for the following products.
View Details
Written procedures are not established for evaluations conducted at least annually to review records associated with a representative number of batches
H J Harkins Company Inc dba Pharma Pac
03 Mar 2023 Normal Justification: The observation specifically mentions the lack of annual evaluations, which is a core requirement of Annual Product Quality Review.
Excerpt: Your firm has not conducted any annual evaluations for the products you repack.
View Details
Written procedures are not followed for evaluations conducted at least annually to review records associated with a representative number of batches
Sina Health Inc
13 Jan 2023 Normal Justification: Annual Product Quality Review is directly linked since the observation indicates a failure to conduct required annual evaluations.
Excerpt: Your firm has not completed (b) (4) evaluations from 2017-2021.
View Details
The responsibilities and procedures applicable to the quality control unit are not fully followed
Orly International, Inc.
20 Dec 2022 Normal Justification: Annual product quality review ensures continuous product suitability and quality consistency.
Excerpt: Your firm does not perform annual product reviews for OTC hand sanitizer and antifungal drug products.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.